Gregory Russotti
Vermogen: 1 M $ op 31-05-2026
Vermogen: 1 M $ op 31-05-2026
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. since 2023.
Formerly, Dr. Russotti was VP, Cell Therapy Development and Operations at Celgene Corp.
from 2013 to 2019.
Education includes a doctorate from Rutgers State University of New Jersey conferred in 1996, and undergraduate and graduate degrees from Rensselaer Polytechnic Institute conferred in 1988 and 1990, respectively.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 12-06-2026 | 605.092 ( 0,34% ) | 1 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2020 |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Consultant / Adviseur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 31-12-2019 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Finance |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau